the aid library

LIST OPTIONS

Filter

5811

Download (474)

View PDF (786)

Operational Guidelines on Community Care Centres

National AIDSControl (NACO), Government of India; Ministry of Health and Family Welfare (2007) C1

Download (294)

View PDF (422)

Lao People’s Democratic Republic-WHO Country Cooperation Strategy 2024–2028

World Health Organization WHO (2023) C_WHO

This country cooperation strategy (CCS) outlines how the World Health Organization (WHO) will work with the Lao People’s Democratic Republic over the next five years (2024–2028), supporting the implementation of the five-year health sector development plans and the Health Sector Reform Strategy ...2021–2030 to attain the Sustainable Development Goals (SDGs) by 2030. The Lao People’s Democratic Republic experienced substantial economic growth in the 30 years prior to the coronavirus disease (COVID-19) pandemic, contributing to reduced poverty and significant progress toward the SDGs. However, the COVID-19 pandemic brought this development to a halt. It was anticipated that the COVID-19 recovery and the tremendous population growth in recent years would provide opportunities for a shift toward more sustainable and inclusive development in the years ahead. In 2023, however, the contrary was the case. Rural residents, including many ethnic minorities, continued to face marginalization because of limited access to education, health care and economic opportunities. Despite the challenges of COVID-19 and other disease outbreaks, the country has made significant improvements in health. Nonetheless, progress has been uneven and not everyone has benefited from these achievements. In the mountainous region, many people lack access to quality health care because of the unequal distribution of well-trained health-care workers. Preventable deaths due to poor-quality health care for children and newborns, infants and mothers remain a concern, as do communicable diseases such as sexually transmitted infections and tuberculosis. The increasing burden of noncommunicable diseases and the health impact of worsening climate change further heighten the need for strengthened and resilient health systems, which are at risk due to an underfunded health sector and weak economy. This CCS aims to address remaining and future challenges as well as health needs while creating an impact that is sustainable. It identifies three strategic priorities and nine deliverables (Table 1) to support the attainment of the national vision of Health for all by all, as articulated in the 9th Health Sector Development Plan 2021–2025. It contributes to the country’s goals to achieve universal health coverage, graduate from least developed country status by 2026 and attain SDGs by 2030. more

Download (3515)

View PDF (764)

National Guidelines for TB, DR-TB and Leprosy in Ethiopia
recommended

Federal Ministry of Health, Ethiopia (2017) C1

6th edition

Download (1254)

View PDF (1563)

WHO Guidelines for the Treatment of Neisseria gonorrhoeae
recommended

Santesso, N.; J. Wasserheit, H. Schünemann, et cl. World Health Organization (WHO) (2016) C_WHO

Download (244)

View PDF (274)

Directrices consolidadas sobre la salud y los derechos sexuales y reproductivos de las mujeres que viven con VIH

Organización Mundial de la Salud (2017) C_WHO

Se calcula que en 2015 había en el mundo 17,8 millones de mujeres de 18 años o mayores infectadas por el VIH, cifra que equivale al 51% de los adultos que viven con VIH. Las adolescentes y las jóvenes se ven especialmente afectadas; en 2015 constituían el 60% de los individuos entre 15 a 24 año... more

Download (412)

View PDF (459)

Harmonized health facility assessment (‎HHFA)‎: comprehensive guide

World Health Organisation (WHO) (2023) C_WHO

The HHFA Comprehensive guide serves as the main reference document for planning and implementing a country HHFA. This guide will promote understanding of: What the HHFA is and the information it can and cannot provide. The HHFA modules, questionnaires and CSPro electronic data collection tool. Th... more

Download (273)

View PDF (211)

Guías de diagnóstico, tratamiento y prevención de la tuberculosis

Palmero, D.; Muñiz F. J., de Casado G. C. , et al. (2011) CC

Download (465)

View PDF (877)

TB in India: burden, progress and needs

Kuldeep Singh Sachdeva, Central Tuberculosis Division Ministry of Health and Family Welfare, Government of India (2012) C1

Download (245)

View PDF (331)

Strengthening countries’ capacities to adopt and adapt evidence-based guidelines: a handbook for guideline contextualization

World Health Organization WHO (2023) C_WHO

Trustworthy, evidence-based health guidelines form the basis of national policies affecting both patients and health-care workers. Emphasizing the link between robust evidence and people’s trust in their health systems, Dr Hans Henri P. Kluge, WHO Regional Director for Europe said at the launch ev... more

Download (556)

View PDF (1025)

Guía clínica para la eliminación de la transmisión maternoinfantil del VIH y de la sífilis congénita en América Latina y el Caribe

Pan American Health Organization PAHO; World Health Organization, Regional Office for the Americas; DGVS; et al. (2010) C_WHO

Download (6492)

View PDF (901)

Standard Operating Procedures for TB Microscopy for Ghana

Ghana Health Service; Ministry of Health, Ghana (2014) C1

Download (405)

View PDF (579)

Therapeutics and COVID-19 (Living Guideline, 10 November 2023)

World Health Organization WHO (2023) C_WHO

WHO has updated its guidelines for COVID-19 therapeutics, with revised recommendations for patients with non-severe COVID-19. This is the 13th update to these guidelines. Updated risk rates for hospital admission in patients with non-severe COVID-19 The guidance includes updated risk rates for... hospital admission in patients with non-severe COVID-19. The current COVID-19 virus variants tend to cause less severe disease while immunity levels are higher due to vaccination, leading to lower risks of severe illness and death for most patients. This update includes new baseline risk estimates for hospital admission in patients with non-severe COVID-19. The new ‘moderate risk’ category now includes people previously considered to be high risk including older people and/or those with chronic conditions, disabilities, and comorbidities of chronic disease. The updated risk estimates will assist healthcare professionals to identify individuals at high, moderate or low risk of hospital admission, and to tailor treatment according to WHO guidelines: **High: **People who are immunosuppressed remain at higher risk if they contract COVID-19, with an estimated hospitalization rate of 6%. **Moderate: **People over 65 years old, those with conditions like obesity, diabetes and/or chronic conditions including chronic obstructive pulmonary disease, kidney or liver disease, cancer, people with disabilities and those with comorbidities of chronic disease are at moderate risk, with an estimated hospitalization rate of 3%. Low: Those who are not in the high or moderate risk categories are at low risk of hospitalization (0.5%). Most people are low risk. Review of COVID-19 treatments for people with non-severe COVID-19 WHO continues to strongly recommend nirmatrelvir-ritonavir (also known by its brand name ‘Paxlovid’) for people at high-risk and moderate risk of hospitalization. The recommendations state that nirmatrelvir-ritonavir is considered the best choice for most eligible patients, given its therapeutic benefits, ease of administration and fewer concerns about potential harms. Nirmatrelvir-ritonavir was first recommended by WHO in April 2022. If nirmatrelvir-ritonavir is not available to patients at high-risk of hospitalization, WHO suggests the use of molnupiravir or remdesivir instead. WHO suggests against the use of molnupiravir and remdesivir for patients at moderate risk, judging the potential harms to outweigh the limited benefits in patients at moderate risk of hospital admission. For people at low risk of hospitalization, WHO does not recommend any antiviral therapy. Symptoms like fever and pain can continue to be managed with analgesics like paracetamol. WHO also recommends against use of a new antiviral (VV116) for patients, except in clinical trials. The update also includes a strong recommendation against the use of ivermectin for patients with non-severe COVID-19. WHO continues to advise that in patients with severe or critical COVID-19, ivermectin should only be used in clinical trials. more

External Link

Tuberculosis and comorbidities in urban areas in Argentina. A gender and age perspective ,

Echazarreta, A.; Zerbini E. De Sandro j., et al. 2018 (2018) CC

180 Biomédica 2018;38:180-8

Download (386)

View PDF (593)

Raport anual de progres (2014)

Centrul Pentru Politici și Analize în Sănătate (2014) C2

Privind implementarea proiectului „sporirea rolului pacientului și a comunității în controlul Tuberculozei în moldova” anul 2014. Raport elaborat de Centrul pentru Politici și Analize în Sănătate.

Download (1529)

View PDF (1088)

Guidelines for the Management of Drug Resistant Tuberculosis in Kenya

Ministry of Public Health and Sanitation, Kenya (2010) CC

Download (297)

View PDF (474)

Preparedness and Resilience for Emerging Threats Module 1: Planning for respiratory pathogen pandemics

World Health Organization WHO (2024) C_WHO

Through technical consultations with countries and partners, WHO has led the development of Preparedness and Resilience for Emerging Threats Module 1: Planning for respiratory pathogen pandemics. Version 1.0. The Module, currently available as an advanced draft, builds on previous pandemic lessons a... more

Download (267)

View PDF (325)

Tuberculosis. Manejo casos sospechosos

Ministerio de Salud, Argentina (2022) CC

Download (1302)

View PDF (1162)

Technical brief: improving surgical male circumcision practice - urethral fistula: diagnosis, first management and prevention

World Health Organization WHO (2021) C_WHO

External Link

Factors associated with tuberculosis treatment failure in the Central East Health region of Burkina Faso

Diallo A., D. L. Dahourou, T. T. E. Dah et al. Panafrican Med Jounal (2018) C2

Tuberculosis treatment failure results in increased risk of morbidity, drug resistance, transmission and mortality. There are few data about tuberculosis treatment outcomes in Burkina Faso. The current study investigated the factors associated with tuberculosis treatment failure in the central east ... more

Download (6938)

View PDF (1573)

Guidelines on programmatic management of drug resistant tuberculosis in Ethiopia
recommended

Ministry of Health Ethiopia (2014) CC

2nd edition

National Guidelines for TB, DR-TB and Leprosy in Ethiopia recommended

WHO Guidelines for the Treatment of Neisseria gonorrhoeae recommended

Guidelines on programmatic management of drug resistant tuberculosis in Ethiopia recommended

National Guidelines for TB, DR-TB and Leprosy in Ethiopia
recommended

WHO Guidelines for the Treatment of Neisseria gonorrhoeae
recommended

Guidelines on programmatic management of drug resistant tuberculosis in Ethiopia
recommended